SEC 13F Intelligence

Skandinaviska Enskilda Banken AB (Publ) / REGN

Skandinaviska Enskilda Banken AB (Publ)’s Regeneron Pharmaceuticals Position

Does Skandinaviska Enskilda Banken AB (Publ) own Regeneron Pharmaceuticals (REGN)? Not currently — the last reported position was 56.6K shares worth $44M in Q4 2025; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$44M
Q4 2025
Shares
56.6K
% of Portfolio
+0.18%
Quarters Held
29
position exited

Position History REGN

Reported value by quarter
Q4 ’18: $49MQ4 ’18Q1 ’19: $54MQ2 ’19: $17MQ3 ’19: $12MQ4 ’19: $55MQ4 ’19Q1 ’20: $57MQ2 ’20: $61MQ3 ’20: $58MQ4 ’20: $56MQ4 ’20Q1 ’21: $40MQ2 ’21: $31MQ3 ’21: $66MQ4 ’21: $128MQ4 ’21Q1 ’22: $107MQ2 ’22: $66MQ3 ’22: $86MQ4 ’22: $72,376Q4 ’22Q1 ’23: $73,468Q2 ’23: $71,807Q3 ’23: $62,886Q4 ’23: $67MQ4 ’23Q1 ’24: $71MQ2 ’24: $78MQ3 ’24: $79MQ4 ’24: $48MQ4 ’24Q1 ’25: $43MQ2 ’25: $36MQ3 ’25: $32MQ4 ’25: $44MQ4 ’25filingsflow.com
QuarterSharesValue% of Portfolio
Q4 202556.6K$44M+0.18%
Q3 202557.0K$32M+0.13%
Q2 202568.1K$36M+0.16%
Q1 202568.1K$43M+0.21%
Q4 202468.3K$48M+0.22%
Q3 202475.2K$79M+0.36%
Q2 202473.8K$78M+0.37%
Q1 202474.0K$71M+0.35%
Q4 202375.9K$67M+0.39%
Q3 202376.4K$62,886+0.41%
Q2 202399.9K$71,807+0.47%
Q1 202389.4K$73,468+0.51%
Q4 2022100.3K$72,376+0.54%
Q3 2022125.2K$86M+0.67%
Q2 2022112.0K$66M+0.49%
Q1 2022153.3K$107M+0.63%
Q4 2021199.6K$128M+0.66%
Q3 2021108.7K$66M+0.36%
Q2 202155.8K$31M+0.19%
Q1 202183.8K$40M+0.26%
Q4 2020115.9K$56M+0.39%
Q3 2020104.1K$58M+0.43%
Q2 202098.4K$61M+0.50%
Q1 2020117.2K$57M+0.61%
Q4 2019146.5K$55M+0.43%
Q3 201942.9K$12M+0.10%
Q2 201955.4K$17M+0.15%
Q1 2019132.2K$54M+0.50%
Q4 2018131.0K$49M+0.44%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Skandinaviska Enskilda Banken AB (Publ)’s full portfolio or all institutional holders of REGN.